Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Taladegib |
Synonyms | |
Therapy Description |
Taladegib (LY-2940680) inhibits Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (Cancer Res 2011;71(8 Suppl):Abstract nr 2819, PMID: 29483143, PMID: 29453627). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Taladegib | LY2940680|LY-2940680|ENV-101 | SMO Inhibitor 16 | Taladegib (LY-2940680) inhibits Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (Cancer Res 2011;71(8 Suppl):Abstract nr 2819, PMID: 29483143, PMID: 29453627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Terminated | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | GBR | 0 |
NCT05199584 | Phase II | Taladegib | A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | Active, not recruiting | USA | 0 |